Table 4.
Demographic and histological characteristics of women with breast cancer with bone metastases (BM) according their menopausal status.
| Premenopausal Women with BM n = 21 | Postmenopausal Women with BM n = 32 | Statistics | |||
|---|---|---|---|---|---|
| Mean or n (%) | Range | Mean or n (%) | Range | p | |
| Age (years) | 41.8 | 33–53 | 64.4 | 45–84 | <0.0001 |
| BMI (kg/m2) | 24.8 | 13–41 | 25.9 | 17–40 | 0.55 |
| Histological size (mm) | 36.2 | 5–70 | 25.8 | 5–70 | 0.05 |
| Molecular phenotype | |||||
| Luminal A | 8 (36.8%) | 13 (40.6%) | 0.33 | ||
| Luminal B | 4 (21.0%) | 12 (37.5%) | |||
| Triple negative | 7 (31.6%) | 5 (15.6%) | |||
| HER2 | 2 (10.5%) | 2 (6.2%) | |||
| Other metastatic sites | |||||
| -Visceral | 11 (63.1%) | 21 (65.6%) | 1 | ||
| -Brain | 7 (31.6%) | 8 (25.0%) | 0.72 | ||
| Lymphovascular invasion | 6 (31.6%) | 10 (31.2%) | 0.97 | ||
| Positive axillary LN | 12 (63.1%) | 16 (50.0%) | 1 | ||
| Multifocality | 5 (26.3%) | 3 (9.3%) | 0.28 | ||
| Inflammatory Breast cancer | 7 (36.8%) | 5 (15.6%) | 0.20 | ||
BMI: body mass index; LN: lymph node; HER2: Human epidermal growth factor receptor 2.